Market
Which company will release the next major obesity drug post-CagriSema trial by end of 2025?
2
Resolution / Starting Odds
Eli Lilly • 25%
Viking Therapeutics • 25%
Pfizer • 25%
Other • 25%
Official announcements from pharmaceutical companies
Story
Novo Nordisk Shares Drop 27% as CagriSema Misses Weight Loss Target in Phase 3 Trial
Dec 20, 2024, 11:00 AM
Novo Nordisk, Europe's largest company, saw its shares plummet by up to 27%, marking its worst trading day since April 2002, after its experimental obesity drug CagriSema failed to meet weight loss expectations in the Phase 3 REDEFINE 1 trial. The trial showed that patients treated with CagriSema achieved a 22.7% weight reduction after 68 weeks, falling short of the anticipated 25%. Additionally, only 57% of patients reached the highest dose after 68 weeks. Comparatively, patients receiving semaglutide 2.4 mg and cagrilintide 2.4 mg experienced weight losses of 16.1% and 11.8%, respectively, while the placebo group lost 2.3%. The disappointing results led to a significant sell-off, with the stock losing its 200-day moving average at $125 and trading 48% below its June high. Competitors such as Eli Lilly and Viking Therapeutics saw their shares rise in response to the news.
View original story
Similar markets
Pfizer • 25%
Other • 25%
Roche • 25%
GlaxoSmithKline • 25%
Pfizer • 25%
Other • 25%
Johnson & Johnson • 25%
Merck • 25%
Novo Nordisk • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Other • 25%
Johnson & Johnson • 25%
Pfizer • 25%
Roche • 25%
Other • 25%
A new drug from another company • 25%
Novo Nordisk's semaglutide 7.2 mg • 25%
Eli Lilly's Zepbound • 25%
No new major approvals • 25%
Eli Lilly • 33%
Novo Nordisk • 33%
Another competitor • 34%
Other • 25%
Novo Nordisk • 25%
Viking Therapeutics • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Other • 25%
Novo Nordisk • 25%
Other • 25%
Viking Therapeutics • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Other • 25%
Other • 25%
Saxenda • 25%
Wegovy • 25%
Zepbound • 25%
Heart disease • 25%
Brain disorders • 25%
Kidney disease • 25%
Stroke • 25%